$RARE News

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

RBC Capital Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $40

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views

Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $96

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses?

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26

Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $43

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $47

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26